What To Expect From Gilead In Q3 2025
Source: SeekingAlpha
2025-10-24 10:56:43 ET
Well, I am here again with my analysis of Gilead Sciences ( GILD ).
Since my last article, "Gilead Sciences: HIV Leadership Outshines Decline in COVID-19 Drug Sales," was published on 9/2, Gilead shares have risen 8.8%, outperforming the S&P 500 ( SPY ) [5.6% return], as well as the 'bellwether' for the biotech retail investors, the VanEck Biotech ETF ( BBH ) [6.7%]....
Read the full article on Seeking Alpha
For further details see:
What To Expect From Gilead In Q3 2025
Ipsen
NASDAQ: IPSEF
IPSEF Trading
100.0% G/L:
$113.13 Last:
5 Volume:
$0 Open:
IPSEF Latest News
March 09, 2026 02:00:00 am
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
